4 August 2017

Help us Help Others: Participate in a Patient Survey on CDI

Clostridium difficile is the most common health care associated pathogen. Its consequences on the quality of life of patients lack data. If you face or faced a Clostridium difficile infection, please take 20 (...)

18 July 2017

Da Volterra Announces Results of a Study Showing the Clinical and Economic Impact of CDIs in French Hospitals

Da Volterra is pleased to announce today the results from a retrospective study on the epidemiology and costs of Clostridium difficile infections in French hospitals. The study shows that the total costs (...)

9 June 2017

Meet Da Volterra at BIO2017 in San Diego

Our CEO, Florence Séjourné, is pleased to speak at BIO2017 during the Session: Partnerships that De-Risk Research & Development of Antimicrobial Products. Come to listen and learn more on Jun 21, (...)

15 May 2017

Da Volterra Presenting Protection of the Intestinal Microbiota at ASM Microbe 2017

Da Volterra is excited to give an Oral Presentation at ASM Microbe 2017, entitled DAV131A Prevents Alterations of the Intestinal Microbiota and Clostridium difficile Infection in Hamsters Treated with Moxifloxacin (...)

11 April 2017

Da Volterra Anticipating an Invigorating ECCMID 2017

ECCMID 2017 in Vienna, Austria is rapidly approaching the 22-25th of April and Da Volterra is looking forward to an invigorating congress and our CEO, Florence Séjourné will be present.  If (...)

7 December 2016

Da Volterra will present results on CDI burden in French hospitals at RICAI 2016 on December 13th: CDIs represent a major cost for public health insurance

Dr. Thibaut Galvain will present results of a study on CDI burden in French hospitals at RICAI in Paris next week, highlighting a major cost for public health insurance.  This study clearly shows that when (...)

15 November 2016

Da Volterra Enthusiastically Supports World Antibiotic Awareness Week

Da Volterra joins WHO, CDC, and ECDC in actively promoting the World Antibiotic Awareness Week 2016 from November 14-20. This annual event aims to stimulate recognition and understanding of antibiotic resistance (...)

15 November 2016

Da Volterra Joins the European Consortium COMBACTE-NET

Da Volterra joins the IMI-Funded European Consortium COMBACTE-NET to accelerate the development of therapeutic solutions combating antibiotic resistance and bacterial infections

Da Volterra announces today (...)

13 September 2016

Da Volterra is a Proud Sponsor of the 2016 Raising C. diff. Awareness Conference and Will Speak about CDI Prevention

Da Volterra is excited to be a sponsor of the 4th Annual International Raising. C. diff. Awareness Conference and Health Expo in Atlanta on September 20th. Our CEO, Florence Séjourne will be sharing (...)

5 July 2016

Da Volterra Presented Highly Convincing Results of Pre-clinical Studies at ASM 2016 : DAV132 Prevents CDI

Professor Antoine Andremont, founder of Da Volterra, presented a poster at ASM in Boston last month highlighing exciting pre-clinical data. Our product, DAV132 successfully protected hamsters from moxifloxacin, (...)